Posted by Michael Wonder on 09 Mar 2023
Use warranties, not outcomes-based agreements, to make payers whole when a gene therapy fails
9 March 2023 - A decade ago, I had pegged gene and cell therapies as the next frontier. As an investment banker, I was sure they would someday change how patients were treated.
But a question from a biotech CEO started me thinking about not only how to pay for them, but how to offer guarantees for these therapies to payers who rightfully wanted reassurances that they were paying for something that works for their beneficiaries.
